Eton Pharmaceuticals Inc.

05/12/2026 | Press release | Distributed by Public on 05/12/2026 14:32

Eton Pharmaceuticals to Participate in Upcoming Investor Conferences

DEER PARK, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that executive management will participate in three upcoming investor conferences as follows:

  • The 26th Annual B. Riley Securities Investor Conference
    Date: Wednesday, May 20, 2026
    Location: The Ritz-Carlton, Marina Del Rey, California
  • The 23rd Annual Craig-Hallum Institutional Investor Conference
    Date: Thursday, May 28, 2026
    Location: Depot Renaissance Hotel Minneapolis, Minnesota
  • Jefferies Global Healthcare Conference
    Date: Thursday, June 4, 2026 at 9:55-10:25AM ET
    Location: New York, New York
    Webcast: Click Here

There are no presentations for the B. Riley Securities and Craig-Hallum conferences.

About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has ten commercial rare disease products: KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, DESMODA™, GALZIN®, HEMANGEOL®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: [email protected]


Source: Eton Pharmaceuticals

Eton Pharmaceuticals Inc. published this content on May 12, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 12, 2026 at 20:32 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]